Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1982 Jun;69(6):1293–1301. doi: 10.1172/JCI110569

Release of Somatostatin-like Immunoreactivity from Incubated Rat Hypothalamus and Cerebral Cortex

EFFECTS OF GLUCOSE AND GLUCOREGULATORY HORMONES

Michael Berelowitz 1, Daniel Dudlak 1, Lawrence A Frohman 1
PMCID: PMC370202  PMID: 7045160

Abstract

Somatostatin (SRIF) is localized in the hypothalamus, extrahypothalamic brain, and throughout the gastrointestinal tract. Release of gastrointestinal SRIF-like immunoreactivity (SRIF-LI) is under nutrient regulation but the effect of nutrients on neural SRIF-LI is unknown. The present studies examined the effects of glucose uptake and metabolism and hormones influencing glucose disposition on SRIF-LI release from medial basal hypothalamus (MBH) and cerebral cortex (Cx) incubated in Krebs-Ringer bicarbonate containing bacitracin. After a preincubation to achieve stable secretion, tissues were incubated for 20 min in 14 mM glucose (basal) and then, for 20 min in fresh medium with test materials. MBH SRIF-LI release was inversely related to medium glucose concentration with release in the absence of glucose (235±42 pg/MBH per 20 min) more than five times that in the presence of 25 mM glucose (46±4 pg/20 min). In the presence of 14 mM glucose MBH SRIF-LI release was stimulated above basal by agents interfering with glucose uptake including 3-O-methyl-d-glucose (42 mM; 70±5 vs. 42±3 pg/20 min, P < 0.05), phlorizin (50 mM; 351±63 vs. 29±2 pg/20 min, P < 0.001) or cytochalasin B (20 μM; 110±7 vs. 22±2 pg/20 min, P < 0.001). Inhibition of glucose metabolism by 2-deoxy-d-glucose resulted in dose-related stimulation of MBH SRIF-LI release (maximal at 28 mM; 201±28 pg/20 min vs. 32±4 pg/20 min, P < 0.001). Viability of MBH was unimpaired by incubation in the absence of glucose or following exposure to 2-deoxy-d-glucose as determined by retention of SRIF-LI responsiveness to stimulation by potassium (60 mM) or neurotensin (5 μM). In contrast, Cx SRIF-LI release was slightly inhibited by decreases in medium glucose and unaffected by inhibition of glucose uptake or metabolism. These results provide evidence for nutrient regulation of MBH but not Cx SRIF-LI release and may explain inhibition of growth hormone seen in the rat in response to hypoglycemia. Insulin (10 nM-1 μM) stimulated MBH but not Cx SRIF-LI release while glucagon was without effect. Our previous demonstration that MBH SRIF-LI release was stimulated by somatomedin-C, but not insulin at physiologic concentrations, is consistent with an action of insulin through the somatomedin-C receptor at the doses studied. Our studies indicate a regional specificity for the control of SRIF secretion within the brain and suggests the possibility of a role for hypothalamic SRIF in metabolic regulation.

Full text

PDF
1293

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alumets J., Ekelund M., El Munshid H. A., Håkanson R., Lorén I., Sundler F. Topography of somatostatin cells in the stomach of the rat: possible functional significance. Cell Tissue Res. 1979 Nov;202(2):177–188. doi: 10.1007/BF00232233. [DOI] [PubMed] [Google Scholar]
  2. Arimura A., Schally A. V. Increase in basal and thyrotropin-releasing hormone (TRH)-stimulated secretion of thyrotropin (TSH) by passive immunization with antiserum to somatostatin in rats. Endocrinology. 1976 Apr;98(4):1069–1072. doi: 10.1210/endo-98-4-1069. [DOI] [PubMed] [Google Scholar]
  3. BATTAGLIA F. C., RANDLE P. J. Regulation of glucose uptake by muscle. 4. The specificity of monosaccharide-transport systems in rat-diaphragm muscle. Biochem J. 1960 May;75:408–416. doi: 10.1042/bj0750408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barden N., Lavoie M., Dupont A., Côté J., Côté J. P. Stimulation of glucagon release by addition of anti-stomatostatin serum to islets of Langerhans in vitro. Endocrinology. 1977 Aug;101(2):635–638. doi: 10.1210/endo-101-2-635. [DOI] [PubMed] [Google Scholar]
  5. Berelowitz M., Firestone S. L., Frohman L. A. Effects of growth hormone excess and deficiency on hypothalamic somatostatin content and release and on tissue somatostatin distribution. Endocrinology. 1981 Sep;109(3):714–719. doi: 10.1210/endo-109-3-714. [DOI] [PubMed] [Google Scholar]
  6. Berelowitz M., Kronheim S., Pimstone B., Sheppard M. Potassium stimulated calcium dependent release of immunoreactive somatostatin from incubated rat hypothalamus. J Neurochem. 1978 Dec;31(6):1537–1539. doi: 10.1111/j.1471-4159.1978.tb06583.x. [DOI] [PubMed] [Google Scholar]
  7. Berelowitz M., Maeda K., Harris S., Frohman L. A. The effect of alterations in the pituitary-thyroid axis on hypothalamic content and in vitro release of somatostatin-like immunoreactivity. Endocrinology. 1980 Jul;107(1):24–29. doi: 10.1210/endo-107-1-24. [DOI] [PubMed] [Google Scholar]
  8. Berelowitz M., Szabo M., Frohman L. A., Firestone S., Chu L., Hintz R. L. Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science. 1981 Jun 12;212(4500):1279–1281. doi: 10.1126/science.6262917. [DOI] [PubMed] [Google Scholar]
  9. Dollinger H. C., Raptis S., Pfeiffer E. F. Effects of somatostatin on exocrine and endocrine pancreatic function stimulated by intestinal hormones in man. Horm Metab Res. 1976 Jan;8(1):74–78. doi: 10.1055/s-0028-1093677. [DOI] [PubMed] [Google Scholar]
  10. Drewes L. R., Horton R. W., Betz A. L., Gilboe D. D. Cytochalasin B inhibition of brain glucose transport and the influence of blood components on inhibitor concentration. Biochim Biophys Acta. 1977 Dec 15;471(3):477–486. doi: 10.1016/0005-2736(77)90051-7. [DOI] [PubMed] [Google Scholar]
  11. Dubois M. P. Immunoreactive somatostatin is present in discrete cells of the endocrine pancreas. Proc Natl Acad Sci U S A. 1975 Apr;72(4):1340–1343. doi: 10.1073/pnas.72.4.1340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Efendić S., Mattsson O. Effect of somatostatin on intestinal motility. Acta Radiol Diagn (Stockh) 1978;19(2):348–352. doi: 10.1177/028418517801900209. [DOI] [PubMed] [Google Scholar]
  13. Ferland L., Labrie F., Arimura A., Schally A. V. Stimulated release of hypothalamic growth hormone-releasing activity by morphine and pentobarbital. Mol Cell Endocrinol. 1977 Feb;6(4-5):247–252. doi: 10.1016/0303-7207(77)90099-5. [DOI] [PubMed] [Google Scholar]
  14. Ferland L., Labrie F., Jobin M., Arimura A., Schally A. V. Physiological role of somatostatin in the control of growth hormone and thyrotropin secretion. Biochem Biophys Res Commun. 1976 Jan 12;68(1):149–156. doi: 10.1016/0006-291x(76)90022-x. [DOI] [PubMed] [Google Scholar]
  15. Gomez-Pan A., Reed J. D., Albinus M., Shaw B., Hall R. Direct inhibition of gastric acid and pepsin secretion by growth-hormone release-inhibiting hormone in cats. Lancet. 1975 Apr 19;1(7912):888–890. doi: 10.1016/s0140-6736(75)91686-4. [DOI] [PubMed] [Google Scholar]
  16. Goto Y., Carpenter R. G., Berelowitz M., Frohman L. A. Effect of ventromedial hypothalamic lesions on the secretion of somatostatin, insulin, and glucagon by the perfused rat pancreas. Metabolism. 1980 Oct;29(10):986–990. doi: 10.1016/0026-0495(80)90044-x. [DOI] [PubMed] [Google Scholar]
  17. Jaspan J., Polonsky K., Lewis M., Moossa A. R. Reduction in portal vein blood flow by somatostatin. Diabetes. 1979 Oct;28(10):888–892. doi: 10.2337/diab.28.10.888. [DOI] [PubMed] [Google Scholar]
  18. Koerker D. J., Ruch W., Chideckel E., Palmer J., Goodner C. J., Ensinck J., Gale C. C. Somatostatin: hypothalamic inhibitor of the endocrine pancreas. Science. 1974 Apr 26;184(4135):482–484. doi: 10.1126/science.184.4135.482. [DOI] [PubMed] [Google Scholar]
  19. Kronheim S., Berelowitz M., Pimstone B. L. A radioimmunoassay for growth hormone release-inhibiting hormone: method and quantitative tissue distribution. Clin Endocrinol (Oxf) 1976 Nov;5(6):619–630. doi: 10.1111/j.1365-2265.1976.tb03865.x. [DOI] [PubMed] [Google Scholar]
  20. Larsson L. I., Goltermann N., de Magistris L., Rehfeld J. F., Schwartz T. W. Somatostatin cell processes as pathways for paracrine secretion. Science. 1979 Sep 28;205(4413):1393–1395. doi: 10.1126/science.382360. [DOI] [PubMed] [Google Scholar]
  21. Lee S. L., Havlicek V., Panerai A. E., Friesen H. G. High K+-induced release of somatostatin from the cortical preparation of rat brain. Experientia. 1979 Mar 15;35(3):351–352. doi: 10.1007/BF01964347. [DOI] [PubMed] [Google Scholar]
  22. MORGAN H. E., REGEN D. M., PARK C. R. IDENTIFICATION OF A MOBILE CARRIER-MEDIATED SUGAR TRANSPORT SYSTEM IN MUSCLE. J Biol Chem. 1964 Feb;239:369–374. [PubMed] [Google Scholar]
  23. Maeda K., Frohman L. A. Release of somatostatin and thyrotropin-releasing hormone from rat hypothalamic fragments in vitro. Endocrinology. 1980 Jun;106(6):1837–1842. doi: 10.1210/endo-106-6-1837. [DOI] [PubMed] [Google Scholar]
  24. McDaniel M., Roth C., Fink J., Fyfe G., Lacy P. Effects of cytochalasins B and D on alloxan inhibition of insulin release. Biochem Biophys Res Commun. 1975 Oct 27;66(4):1089–1096. doi: 10.1016/0006-291x(75)90469-6. [DOI] [PubMed] [Google Scholar]
  25. Patel Y. C., Reichlin S. Somatostatin in hypothalamus, extrahypothalamic brain, and peripheral tissues of the rat. Endocrinology. 1978 Feb;102(2):523–530. doi: 10.1210/endo-102-2-523. [DOI] [PubMed] [Google Scholar]
  26. Phillips L. S., Vassilopoulou-Sellin R. Somatomedins (first of two parts). N Engl J Med. 1980 Feb 14;302(7):371–380. doi: 10.1056/NEJM198002143020704. [DOI] [PubMed] [Google Scholar]
  27. Schlegel W., Raptis S., Harvey R. F., Oliver J. M., Pfeiffer E. F. Inhibition of cholecystokinin-pancreozymin release by somatostatin. Lancet. 1977 Jul 23;2(8030):166–168. doi: 10.1016/s0140-6736(77)90182-9. [DOI] [PubMed] [Google Scholar]
  28. Schusdziarra V., Harris V., Arimura A., Unger R. H. Evidence for a role of splanchnic somatostatin in the homeostasis of ingested nutrients. Endocrinology. 1979 Jun;104(6):1705–1708. doi: 10.1210/endo-104-6-1705. [DOI] [PubMed] [Google Scholar]
  29. Schusdziarra V. Somatostatin--a regulatory modulator connecting nutrient entry and metabolism. Horm Metab Res. 1980 Nov;12(11):563–577. doi: 10.1055/s-2007-999203. [DOI] [PubMed] [Google Scholar]
  30. Schusdziarra V., Zyznar E., Rouiller D., Boden G., Brown J. C., Arimura A., Unger R. H. Splanchnic somatostatin: a hormonal regulator of nutrient homeostasis. Science. 1980 Feb 1;207(4430):530–532. doi: 10.1126/science.7352262. [DOI] [PubMed] [Google Scholar]
  31. Sheppard M. C., Kronheim S., Pimstone B. L. Stimulation by growth hormone of somatostatin release from the rat hypothalamus in vitro. Clin Endocrinol (Oxf) 1978 Dec;9(6):583–586. doi: 10.1111/j.1365-2265.1978.tb01518.x. [DOI] [PubMed] [Google Scholar]
  32. Taniguchi H., Utsumi M., Hasegawa M., Kobayashi T., Watanabe Y., Murakami K., Seki M., Tsutou A., Makimura H., Sakoda M. Physiologic role of somatostatin. Insulin release from rat islets treated by somatostatin antiserum. Diabetes. 1977 Jul;26(7):700–702. doi: 10.2337/diab.26.7.700. [DOI] [PubMed] [Google Scholar]
  33. Tannenbaum G. S., Epelbaum J., Colle E., Brazeau P., Martin J. B. Antiserum to somatostatin reverses starvation-induced inhibition of growth hormone but not insulin secretion. Endocrinology. 1978 Jun;102(6):1909–1914. doi: 10.1210/endo-102-6-1909. [DOI] [PubMed] [Google Scholar]
  34. Wasada T., Howard B., Dobbs R. E., Unger R. H. Evidence for a role of free fatty acids in the regulation of somatostatin secretion in normal and alloxan diabetic dogs. J Clin Invest. 1980 Sep;66(3):511–516. doi: 10.1172/JCI109882. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES